Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Baricitinib

Brand: Olumiant®
NICE TA: 466
Indication: Moderate to severe rheumatoid arthritis (NICE TA466)
Disease category: Musculoskeletal system
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Baricitinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if:

•disease is severe (a disease activity score [DAS28] of more than 5.1) and
•the company provides baricitinib with the discount agreed in the patient access scheme.

Baricitinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if:

•disease is severe (a DAS28 of more than 5.1) and
•they cannot have rituximab and
•the company provides baricitinib with the discount agreed in the patient access scheme.

Baricitinib can be used as monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in sections 1.1 and 1.2 are met.

Continue treatment only if there is a moderate response measured using European League Against Rheumatism (EULAR) criteria at 6 months after starting therapy. After an initial response within 6 months, withdraw treatment if at least a moderate EULAR response is not maintained.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red